This shift value, in our understanding, represents the difference in the time of cancer occurrence; therefore, this means that patients with BRCA1/BRCA2 mutations are diagnosed with breast or ovary cancer approximately two years earlier than patients without such mutations. The gene discussed is BRCA2; the disease is ovarian cancer.